A novel therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bind

ABSTRACT: Chemotherapy remains a commonly used and important treatment option for metastatic breast cancer. A majority of ER+ metastatic breast cancer patients ultimately develop resistance to chemotherapy, resulting in progression. We hypothesized that an "evolutionary double-bind", where treatment with one drug improves the response to a different agent, increased the effectiveness and durability of responses to chemotherapy by exploiting vulnerabilities in acquired resistance mechanisms. Evolutionary models can be used in cancer to identify alternative treatment strategies that capitalize on acquired vulnerabilities and resistance traits for improved outcomes. ER+ breast cancer cell lineages sensitive and resistant to chemotherapy are grown in spheroids with varied population frequencies to meas

SUBMITTER: Rena Emond 

PROVIDER: S-SCDT-10_1038-S44320-026-00191-Z | biostudies-other |

REPOSITORIES: biostudies-other